36C24E24Q0126.docx
DOCX document 14 KB Posted
- Attached to
- AN42--Research Product - Synthesis and Mfg Hydroxy for Clinical Trial - University of Minnesota
- Solicitation number
- 36C24E24Q0126
About this file
This document is a Special Notice from the Department of Veterans Affairs (VA) Office of Research and Development, Regional Procurement Office East, regarding a sole source requirement for the University of Minnesota to optimize a synthetic process and manufacture 2-gram quantities of the active ingredient hydroxychloroquine sulfate for use in a Phase I/II clinical trial. The requirement will take place at a VA facility in Philadelphia, PA. The sole source is justified under FAR 6.302-1 as the agency has determined the University of Minnesota is the only responsible source. Interested parties who believe they can meet the requirement may submit capability statements by September 11, 2024, at 10:00 AM EST. The agency will make a determination on whether to compete the requirement based on the responses received.
View the file
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Special Notice Special Notice
| SUBJECT* |
| Research Product - Synthesis and Mfg Hydroxy for Clinical Trial - University of Minnesota |
GENERAL INFORMATION
| CONTRACTING OFFICE’S ZIP CODE* |
| 15215-1802 |
| SOLICITATION NUMBER* |
| 36C24E24Q0126 |
| RESPONSE DATE/TIME/ZONE |
| 09-11-2024 10:00 am EASTERN TIME, NEW YORK, USA |
| ARCHIVE |
| 15 DAYS AFTER THE RESPONSE DATE |
| RECOVERY ACT FUNDS |
| N |
| PRODUCT SERVICE CODE* |
| AN42 |
| NAICS CODE* |
| 541715 |
| CONTRACTING OFFICE ADDRESS |
| Veterans Health Administration |
Regional Procurement Office East Building 32 Suite 1A1111 1010 Delafield Road Pittsburgh PA 15215-1802
POINT OF CONTACT*
Contracting Officer Michael Haydo michael.haydo@va.gov
ADDITIONAL INFORMATION
AGENCY’S URL
URL DESCRIPTION
AGENCY CONTACT’S EMAIL ADDRESS
EMAIL DESCRIPTION
DESCRIPTION
The Veteran’s Administration (VA) Office of Research and Development, Regional Procurement Office – East in Pittsburgh, PA intends to negotiate on a sole source basis with the University of Minnesota based in Minneapolis, MN on behalf of the VA Philadelphia Healthcare System. The requirement is to optimize a synthetic process and analytical methodology for the active ingredient hydroxychloroquine sulfate on a 2-gram scale for clinical use as an investigational drug as well as to manufacture this ingredient on a 2-gram scale for clinical using in a Phase I/II clinical trial.
The requirement will take place at a VA facility Philadelphia, PA. The sole source is pursuant to FAR 6.302-1 Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. This notice of intent is not a request for competitive proposals, however; any responsible source who believes it is capable of meeting the requirement may submit a capability statement and supporting documentation to the contracting office no later than Wednesday, Sept 11, 2024, (10:00 AM, EST). Interest/capability statements may be sent to Michael Haydo at Michael.haydo@va.gov. No telephone responses will be accepted. A determination not to compete the proposed requirement based upon the responses to this notice is solely within the discretion of the Government.
| *= Required Field |
| Special Notice |
Special Notice
File details come from the government source that posted it. Updated .